216例中晚期原发性肝细胞癌介入化疗及综合治疗的疗效比较

Therapeutic efficacy comparation between transcather arterial chemoembolization and comprehensive therapy in 216 patients with primary advanced hepatocellular carcinoma

目的比较单纯肝动脉化疗栓塞术（TACE）和联合腹腔灌注、中药辅助治疗及免疫治疗原发性肝细胞癌的疗效及毒副作用。方法将216例原发性肝细胞癌随机分为两组，A组104例，单纯行TACE；B组112例，TACE＋腹腔灌注化疗＋中药辅助治疗＋免疫治疗。结果近期有效率A组为28．84％，B组为34．82％；4年生存率A组1．92％，B组3．57％，差异有统计学意义（P〈0．05）。治疗后两组均无严重并发症发生。结论B组的近期疗效和4年生存率均优于A组、两组副反应率差异无统计学意义。

Objective To compare the therapeutic efficacy and adverse effects between transcather arte- rial chemoembolization（TACE） and comprehensive therapy in primary advanced heptocellular carcinoma（HCC）. Methods 216 patients with primary HCC were arranged randomly into two groups：104 （group A） were treated with TACE alone, the rest（ group B）were treated with TACE combined with intraperitoneal perfusion chemothera- py, Chinese herbs and immunotherapy. The therapeutic efficacy and adverse effects were analysed and compared between two groups. Results The CR ＋ PR rates were 28.84% in group A and 34. 82% in group B. The 4-year survival rates were 1.92% in group A and 3.87% in group B（P 〈0.05）. There were no severe side effects in both groups. Conclusions The short-term effective rate and 4-year survival rate in comprehensive treatment group were superior to the control group. Therefore, the comprehensive treatment is worthwhile to use in primary advanced hepatocellular carcinoma.